AU2018272688B2 - Cell cryopreservation formulation and cell recovery method - Google Patents

Cell cryopreservation formulation and cell recovery method Download PDF

Info

Publication number
AU2018272688B2
AU2018272688B2 AU2018272688A AU2018272688A AU2018272688B2 AU 2018272688 B2 AU2018272688 B2 AU 2018272688B2 AU 2018272688 A AU2018272688 A AU 2018272688A AU 2018272688 A AU2018272688 A AU 2018272688A AU 2018272688 B2 AU2018272688 B2 AU 2018272688B2
Authority
AU
Australia
Prior art keywords
cells
preparation
cryopreservation
cell
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018272688A
Other languages
English (en)
Other versions
AU2018272688A1 (en
Inventor
Jiaping HE
Yonglai HU
Chao Li
Nanjing LIN
Liping Liu
Xiaoyu Liu
Xin Liu
Zhe SUN
Fei Wang
Shuqian YU
Li Zhang
Jiawei ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Abelzeta Ltd
Original Assignee
Shanghai Abelzeta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Abelzeta Ltd filed Critical Shanghai Abelzeta Ltd
Publication of AU2018272688A1 publication Critical patent/AU2018272688A1/en
Application granted granted Critical
Publication of AU2018272688B2 publication Critical patent/AU2018272688B2/en
Assigned to Shanghai AbelZeta Ltd. reassignment Shanghai AbelZeta Ltd. Request for Assignment Assignors: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD., CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018272688A 2017-05-24 2018-05-24 Cell cryopreservation formulation and cell recovery method Active AU2018272688B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710375424.XA CN108925548A (zh) 2017-05-24 2017-05-24 一种冻存细胞制剂及细胞复苏方式
CN201710375424.X 2017-05-24
PCT/CN2018/088246 WO2018214943A1 (zh) 2017-05-24 2018-05-24 一种冻存细胞制剂及细胞复苏方式

Publications (2)

Publication Number Publication Date
AU2018272688A1 AU2018272688A1 (en) 2019-12-19
AU2018272688B2 true AU2018272688B2 (en) 2021-05-27

Family

ID=64396262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018272688A Active AU2018272688B2 (en) 2017-05-24 2018-05-24 Cell cryopreservation formulation and cell recovery method

Country Status (8)

Country Link
US (1) US20200170242A1 (enExample)
EP (1) EP3632207A4 (enExample)
JP (1) JP7303184B2 (enExample)
KR (1) KR102350423B1 (enExample)
CN (1) CN108925548A (enExample)
AU (1) AU2018272688B2 (enExample)
NZ (1) NZ759568A (enExample)
WO (1) WO2018214943A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
AU2021245671A1 (en) * 2020-03-31 2022-10-20 Cell Exosome Therapeutics Inc. Cell preservation method
AU2021324669A1 (en) * 2020-08-10 2023-02-23 Angiocrine Bioscience, Inc. Cryopreserved endothelial cell compositions
TW202245811A (zh) * 2021-02-03 2022-12-01 美商異基因治療有限公司 用於ｃａｒ ｔ細胞藥物產品的調配物與製程
US20220354108A1 (en) * 2021-05-04 2022-11-10 Tissue Testing Technologies Llc Preservation methods using trehalose with other cryoprotectants being absent from the cryopreservation protocol
CN113994951A (zh) * 2021-11-17 2022-02-01 晋文娟 一种cik细胞冻存液及冻存方法
CN114097771B (zh) * 2021-12-15 2022-10-14 珠海贝索细胞科学技术有限公司 一种细胞保存液及其应用和细胞保存方法
CN115136955A (zh) * 2022-08-03 2022-10-04 深圳宾德生物技术有限公司 细胞冻存液及其制备方法和应用
CN116058363B (zh) * 2023-01-13 2025-10-28 杭州中赢生物医疗科技有限公司 一种增加nk细胞冻存复苏后活性的方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713245B2 (en) * 1998-07-06 2004-03-30 Diacrin, Inc. Methods for storing neural cells such that they are suitable for transplantation
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7270946B2 (en) * 2002-10-04 2007-09-18 Organ Recovery Systems, Inc. Method for treatment of cellular materials with sugars prior to preservation
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20070025961A1 (en) 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
CN102119936B (zh) * 2011-03-07 2012-12-12 李荣旗 制备利用人羊膜间充质细胞治疗缺血性脑损伤注射液的方法及其注射液
CN103461322B (zh) * 2012-06-07 2016-08-03 西比曼生物科技（上海）有限公司 用于冻存复苏后的细胞的保存液
CN102907416B (zh) * 2012-08-01 2016-08-03 西比曼生物科技（上海）有限公司 一种可维持细胞活性的组织冻存液
CN102792947B (zh) * 2012-09-03 2014-03-26 四川新生命干细胞科技股份有限公司 一种间充质干细胞冻存液及注射液
CN102908364A (zh) * 2012-11-14 2013-02-06 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗儿童扩张型心肌病药物中的应用
EP3066193B1 (en) 2013-11-04 2024-07-10 Isopogen Pty Ltd Cell culture method
CN114540266A (zh) 2014-07-07 2022-05-27 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
CN104430301A (zh) * 2014-11-18 2015-03-25 成都康华生物制品有限公司 一种提高人二倍体细胞存活率的方法
US20180116956A1 (en) * 2015-04-02 2018-05-03 Stegi-Ra Trust Composition for use in treating celiac disease
CN104857022A (zh) * 2015-05-21 2015-08-26 北京青藤谷禧干细胞科技研究院有限公司 一种间充质干细胞注射液、制备方法及其应用
CN105394026B (zh) * 2015-10-31 2017-09-29 北京军科联合干细胞生物科技有限公司 一种造血干细胞冻存新方法
CN105325402A (zh) * 2015-11-13 2016-02-17 黄林海 一种用于玻璃化冻存骨髓间充质干细胞的冻存保护剂
CN105477017A (zh) * 2015-12-03 2016-04-13 深圳爱生再生医学科技有限公司 治疗糖尿病足的混合干细胞制剂及其制备方法
CN105660606B (zh) * 2016-03-10 2018-04-03 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CN106665560B (zh) * 2017-01-16 2021-02-05 哈尔滨医科大学 一种直接静脉回输的免疫细胞冻存液及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D.N. WORSHAM, et al. Transplantation and Cellular Engineering. (first published 28 April 2017) Vol.57, pp.1555-1565 *

Also Published As

Publication number Publication date
KR102350423B1 (ko) 2022-01-11
WO2018214943A1 (zh) 2018-11-29
US20200170242A1 (en) 2020-06-04
EP3632207A4 (en) 2021-03-10
KR20200073171A (ko) 2020-06-23
JP2020520680A (ja) 2020-07-16
NZ759568A (en) 2023-01-27
AU2018272688A1 (en) 2019-12-19
JP7303184B2 (ja) 2023-07-04
EP3632207A1 (en) 2020-04-08
CN108925548A (zh) 2018-12-04

Similar Documents

Publication Publication Date Title
AU2018272688B2 (en) Cell cryopreservation formulation and cell recovery method
WO2018113796A1 (zh) 一种可临床使用的细胞冻存液
CN103563888B (zh) 细胞冻存液
US12414558B2 (en) Method for administering umbilical cord blood or peripheral blood
CN110959606B (zh) 一种免疫效应细胞冻存液及其用途
CN105994254A (zh) 一种dc细胞的冻存液及冻存方法
CN105941389A (zh) 一种无动物源血清的细胞冻存液
CN110583622A (zh) 一种t细胞无血清冻存液及其使用方法
CN109315386A (zh) 一种可用于造血干细胞或淋巴细胞的冻存液及冻存方法
WO2021190620A1 (zh) 细胞保存液及其试剂盒
CN106047798A (zh) 一种适用于高密度细胞培养体系的羊水细胞培养基
CN114403127A (zh) 一种间充质干细胞冷藏保护液及保存方法
WO2021213446A1 (zh) 生物样品低温储存
HK40017286A (en) Cell cryopreservation formulation and cell recovery method
WO2021240169A1 (en) Cryopreserving macrophages
CN118680163A (zh) 一种脐带间充质干细胞注射液冻存液、制备方法及应用
CN110679588A (zh) 一种嵌合抗原受体t细胞冻存介质及用途
WO2018214942A1 (zh) 一种冻存细胞试剂盒
CN109122666A (zh) 一种复苏即用型红细胞冷冻保护剂及使用方法
NL2034495B1 (en) Stem cell cryopreservation protective agent, preparation method, and application thereof
CN103289957A (zh) 干细胞样肺癌细胞制备及其抗原组合物负载树突状细胞的方法与试剂盒
CN111374123B (zh) 中性氨基酸作为细胞低温保护剂的使用方法及其应用
CN116941605A (zh) 一种免疫细胞冻存液及冻存细胞的方法
Lascano et al. Preoperative esophageal varices is associated with increased likelihood of transplant after elective hernia surgery
CN118177187A (zh) 一种非预混式可注射级细胞冷冻保护试剂盒及其制备方法与应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SHANGHAI ABELZETA LTD.

Free format text: FORMER OWNER(S): CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.; CELLULAR BIOMEDICINE GROUP (WUXI) LTD.